Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Pertuzumab, Trastuzumab SC, and Taxane in HER2+ mBC
NCT02019277Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2013
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab, trastuzumab in HER2-positive metastatic breast cancer, sponsored by Roche. Started Dec 2013; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02019277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019277.